Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors i... - 0 views
advances.sciencemag.org/...e1501924.full
progesterone PR progesterone receptors progesterone receptor cancer breast cancer hormones
![](/images/link.gif)
-
The presence and activity of PR significantly affect the prognostic value of ER.
-
The observed loss of PR protein expression in a subset of ER+/PR+ breast cancers, because of hypermethylation or deletion of the PR gene locus, results in the loss of ER prognostic value
-
These findings emphasize the clinical value of assessing both PR and ER expression in breast cancer samples
- ...7 more annotations...
-
PR is an essential modulator of ER-regulated genes but also that it significantly contributes to the prognostic value of ER in ER+/PR+ breast cancers
-
PR-regulated genes have independent prognostic value, and the presence of PR correlates with favorable clinicopathological outcomes
-
this study demonstrates that progestin-activated PR redirects ER chromatin binding and functions as a genomic estrogen agonist and as a phenotypic estrogen antagonist in ER+/PR+ breast cancer cells and human tumors
-
In isolation, both hormones activate or inhibit cellular processes in similar directions, although the magnitude of these effects is less for progestin alone than for estrogen alone
-
WOW!! study finds that progesterone through PR activity antagonizes ER protein expression by the cell. This has huge implications in breast cancer and possible prostate cancer. But then again, women don't need progesterone; only estrogen. The presence of PR correlates with improved clinicopathological outcomes. The authors do seem to get confused about progesterone and progestins. They are not one in the same.